当地时间10月3日，艾伯维在一份监管文件中表示，预计其第三季度业绩将计入27亿美元（税前）在研 项目（IPR&D）支出的相关费用。艾伯维表示，受第三季度该笔支出影响，公司第三季度调整后每股 摊薄收益将在1.74至1.78美元之间。同时，艾伯维将全年调整后每股摊薄收益预期从先前预测的11.88- 12.08美元下调至10.38-10.58美元。 来源：智通财经 ...

Drugmaker AbbVie in a regulatory filing on Friday said it expects third-quarter earnings to include a $2.7 billion charge related to in-process research and development (IPR&D) expenses. ...

FORM 8-K Filing Information This section provides administrative details for the Form 8-K filing, including registrant identification and event date [Registrant and Filing Details](index=1&type=section&id=Registrant%20and%20Filing%20Details) This section provides basic identification details for the Form 8-K filing, including the registrant's name, address, and the date of the earliest event reported - Registrant is ABBVIE INC., located at 1 North Waukegan Road, North Chicago, Illinois[1](index=1&type=chunk)[2](index=2&type=chunk) - The date of the earliest event reported is October 3, 2025[1](index=1&type=chunk) [Securities Registered](index=1&type=section&id=Securities%20Registered) This section lists the classes of securities registered by AbbVie Inc. pursuant to Section 12(b) of the Act, including common stock and various senior notes, along with their trading symbols and the exchanges on which they are registered Securities Registered | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :------------------ | :---------------- | :---------------------------------------- | | Common Stock, $0.01 Par Value | ABBV | New York Stock Exchange, NYSE Texas | | 0.750% Senior Notes due 2027 | ABBV27 | New York Stock Exchange | | 2.125% Senior Notes due 2028 | ABBV28 | New York Stock Exchange | | 2.625% Senior Notes due 2028 | ABBV28B | New York Stock Exchange | | 2.125% Senior Notes due 2029 | ABBV29 | New York Stock Exchange | | 1.250% Senior Notes due 2031 | ABBV31 | New York Stock Exchange | [Item 2.02 Results of Operations and Financial Condition](index=2&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) This section outlines AbbVie's preliminary financial estimates for Q3 2025, highlighting a significant pre-tax acquired IPR&D and milestones expense [Third Quarter 2025 Preliminary Financial Estimates](index=2&type=section&id=Third%20Quarter%202025%20Preliminary%20Financial%20Estimates) AbbVie expects its Q3 2025 GAAP and adjusted non-GAAP earnings to be significantly impacted by a $2.7 billion pre-tax acquired IPR&D and milestones expense, resulting in an unfavorable $1.50 impact per share - Q3 2025 GAAP and adjusted non-GAAP earnings are expected to include **$2.7 billion pre-tax acquired IPR&D and milestones expense**[5](index=5&type=chunk) - This expense represents an unfavorable impact of **$1.50** to both GAAP and adjusted non-GAAP diluted earnings per share[5](index=5&type=chunk) - Results for the quarter ended September 30, 2025, are preliminary and subject to financial statement closing procedures[5](index=5&type=chunk) [Updated Earnings Per Share Guidance](index=2&type=section&id=Updated%20Earnings%20Per%20Share%20Guidance) The company has updated its full-year and third-quarter 2025 adjusted diluted EPS guidance to include the impact of the acquired IPR&D and milestones expense, which was previously excluded from forecasts due to its uncertain nature - AbbVie does not typically forecast acquired IPR&D and milestones expense due to uncertainty in occurrence and timing[6](index=6&type=chunk) Updated Adjusted Diluted EPS Guidance (including Q3 2025 IPR&D expense) | Period | Adjusted Diluted EPS Guidance Range | | :----- | :---------------------------------- | | Full-year 2025 | $10.38 - $10.58 | | Third Quarter 2025 | $1.74 - $1.78 | - Guidance for 2025, including the estimated acquired IPR&D and milestones expense, is furnished as Exhibit 99.1[7](index=7&type=chunk) [Forward-Looking Statements](index=2&type=section&id=Forward-Looking%20Statements) This section provides a disclaimer regarding the inherent risks and uncertainties associated with forward-looking statements in the report [Disclaimer on Future Performance](index=2&type=section&id=Disclaimer%20on%20Future%20Performance) This standard disclosure warns that some statements in the report are forward-looking and subject to various risks and uncertainties, including intellectual property challenges, competition, R&D difficulties, litigation, regulatory changes, and macroeconomic factors, which could cause actual results to differ materially - Forward-looking statements are identified by words like 'believe,' 'expect,' 'anticipate,' 'project' and similar expressions[9](index=9&type=chunk) - Such statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied[9](index=9&type=chunk) - Risks include challenges to intellectual property, competition, R&D difficulties, adverse litigation, regulatory changes, and global macroeconomic factors[9](index=9&type=chunk) [Item 9.01 Financial Statements and Exhibits](index=2&type=section&id=Item%209.01%20Financial%20Statements%20and%20Exhibits) This section lists the financial statements and exhibits included in the Form 8-K filing [Exhibits Filed](index=2&type=section&id=Exhibits%20Filed) This item lists the exhibits accompanying the Form 8-K, specifically Exhibit 99.1, which provides detailed guidance including the impact of acquired IPR&D and milestones expense, and Exhibit 104 for the Inline XBRL cover page Exhibits | Exhibit No. | Exhibit Description | | :---------- | :------------------ | | 99.1 | Guidance including the impact of acquired IPR&D and milestones expense | | 104 | The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101) | [SIGNATURE](index=4&type=section&id=SIGNATURE) This section formally concludes the Form 8-K filing, indicating due authorization and signature [Report Authorization](index=4&type=section&id=Report%20Authorization) This section formally concludes the Form 8-K filing, indicating that the registrant has duly authorized and signed the report - The report was signed on October 3, 2025, by Scott T. Reents, Executive Vice President and Chief Financial Officer of ABBVIE INC[14](index=14&type=chunk)

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.AbbVie (NYSE: ABBV ) has been on a roll lately. The commercial business is humming, the p ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.AbbVie (NYSE: ABBV ) has been on a roll lately. The commercial business is humming, the p ...

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgent need for energy to support its growth [1][2][3] - A specific company is highlighted as a key player in the AI energy sector, owning critical energy infrastructure assets that are essential for meeting the increasing energy demands of AI technologies [3][7][8] Investment Landscape - Wall Street is investing hundreds of billions into AI, but there is a looming question regarding the energy supply needed to sustain this growth [2] - AI data centers consume vast amounts of energy, comparable to that of small cities, indicating a significant strain on global power grids [2] - The company in focus is positioned to benefit from the surge in demand for electricity driven by AI advancements, making it a unique investment opportunity [3][6] Company Profile - The company is described as a "toll booth" operator in the AI energy boom, collecting fees from energy exports and benefiting from the onshoring trend due to tariffs [5][6] - It possesses critical nuclear energy infrastructure assets, making it integral to America's future power strategy [7] - The company is noted for its ability to execute large-scale engineering, procurement, and construction projects across various energy sectors, including oil, gas, and renewables [7] Financial Position - The company is completely debt-free and has a significant cash reserve, amounting to nearly one-third of its market capitalization, which positions it favorably compared to other energy firms burdened by debt [8][10] - It also holds a substantial equity stake in another AI-related company, providing indirect exposure to multiple growth engines in the AI sector [9] Market Sentiment - There is a growing interest from hedge funds in this company, which is considered undervalued and off-the-radar, trading at less than seven times earnings [10][11] - The company is recognized for delivering real cash flows and owning critical infrastructure, making it a compelling investment choice in the context of the AI and energy sectors [11][12]

CHINA - 2025/09/27: In this photo illustration, the AbbVie logo is seen displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesAbbVie stock (NYSE: ABBV) rallied 11% in a week, largely driven by a key development that boosted the entire sector: Pfizer’s agreement to lower its drug prices for Medicaid and a White House decision to grant a three-year exemption from 100% import tariffs. Since the market sees t ...

About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X ( ...

AbbVie Inc. (NYSE:ABBV) ranks among the stocks with low beta that can beat market volatility. On September 24, Leerink Partners maintained its Outperform rating on AbbVie Inc. (NYSE:ABBV) and raised its price target on the company’s shares from $210 to $243. The increase comes after AbbVie Inc. (NYSE:ABBV) announced on September 11 that it had reached a settlement that would allow generic Rinvoq to be introduced in April 2037, over four years later than Leerink had previously predicted. Pixabay/Public Do ...

Core Viewpoint - AbbVie is facing a cautious outlook following a downgrade by HSBC, yet the company is actively investing in its operations to enhance its manufacturing and research capabilities in response to growing global demand for its products [1][2]. Company Developments - AbbVie has initiated a $70 million expansion at its Bioresearch Center in Worcester, Massachusetts, as part of a broader $10 billion investment in U.S. operations [2]. - The expansion will include new manufacturing areas and a three-story building for laboratories, warehouse, and office spaces, facilitating the transfer of select oncology products from Europe to the U.S. [3]. Stock Performance - AbbVie's stock is currently trading at $244.38, reflecting a 5.55% increase, with a market capitalization of approximately $431.7 billion and a trading volume of 11.28 million shares [4]. - The stock has shown significant growth over the past year, with a lowest price of $163.81 and a highest price of $244.81 today [4].